Many thanks to all our Nimbi, investors, collaborators and of course patients – all absolutely critical to the success of our #TYK2 journey!

"The Book of Nimbus" - with Nimbus Therapeutics becoming 14 years old in May, CEO Jeb Keiper shares some history and frames up our evolving "Chapter 3" lifescivc.com/2023/04/the-bo…

At the 2023 Stanford Drug Discovery Symposium, Dr. Brian Druker discussed his groundbreaking work proving it was possible to shut down cells that enable cancer to grow without harming healthy ones. Learn more (via Genetic Engineering & Biotechnology News): spr.ly/6013OZboz

Next week, Nimbus CBO Abbas Kazimi will participate in the Keynote panel on M&A and Strategic Financing in Today's Biotech Tape at the RBC Global Healthcare Conference in New York City.

Aspirations to industrialize drug discovery is commendable & worth pursuing.Nimbus Therapeutics has seen its path to success through refining target selection & integrating compchem / AI tools at the right time. Lot of humility gained over 14 years to design breakthrough medicines!

Tomorrow, our Nimbi will participate in Bio-Ball 2023, an annual basketball event to benefit Special Olympics MA. This is your last chance to support Team Nimbi as they get ready for an exciting day ahead: bit.ly/3VwNnOw

"The exception is more interesting than the rule." #Biotech reverse merger occasionally turn into >$1B buyout Aduro➡️ $KDNY ➡️$3.2B $NVS shell➡️Medivation➡️$14B $PFE Trimeris➡️Synageva➡️$8.4B ALXN CancerVax➡️Micromet➡️$1.2B $AMGN Biodel➡️Albireo➡️$1B Ipsen shell➡️Cougar➡️$1B JNJ

Big deals and small molecules with Nimbus Therapeutics CEO Jeb Keiper. Full video: biotechtv.com/post/jeb-keipe…

While the 'how' is important in drug discovery, focusing on the 'what' comes out of of the approach matters (insert @Dereklowe). Lots of hype indeed and a self-created race to be the first "AI" drug in the clinic...not sure why, but if patients benefit, that is the winner.

'Know thyself'. So important for biotech's to know their role (target ID, disc., devp't., comm'l, etc.) in getting medicines to patients. Helps to articulate to investors, partners, and employees their business plan, and keeps the entire organization focused on a mission.

This week, Nimbus' Director of Computational Chemistry, Leela Dodda, will present at the Gordon Research Conference on Medicinal Chemistry on how Nimbus uses physics-based machine learning to identify inhibitors for difficult to drug targets.

Great Brian Gormley The Wall Street Journal article today on getting back to returns in biotech; appreciate the Nimbus Therapeutics mention wsj.com/articles/biote…

So fortunate to be nominated by Biotech Week Boston and have our #TYK2 transaction with Takeda recognized. Looking forward to spending the evening with our Nimbi & Takeda colleagues!

After 14 years, our mission to design breakthrough medicines continues! Thank you to our incredible investors for believing in Nimbus and our collective passion to change the course of treatment for patients. Excited to welcome GV to join us on our journey.

Humbled to join Timmerman Traverse in Feb '24 to climb Mt. Kilimanjaro & raise $50K for Damon Runyon Cancer Research Foundation. I have lost family & friends to cancer & supporting research provides important breakthroughs for medicines. Please help me achieve my goal here: bit.ly/3r655NZ

Honored to kickoff the Private Track at #jpm2024 (7:30am Monday!!) with new programs in immunology and data updates on other programs in the ⁦Nimbus Therapeutics⁩ pipeline. More details on LinkedIn and here: businesswire.com/news/home/2024… linkedin.com/posts/jebkeipe…

Great week with the best team in biotech ⁦Nimbus Therapeutics⁩ #jpm2024

There’s a frequent perception among recent entrants to drug discovery world that if we could just find drug candidates faster, this will be a useful accelerant to the overall process. The issue is: this thinking is mostly (but not entirely) incorrect. 🧵 1/